Melatoninas – Nauda, Poveikis, Vartojimas

melatonino papildai miegui

kas-yra-melatoninasDaugelis žmonių pradeda vartoti į melatonino papildus, kad padėtų normalizuoti miego kokybę.

Mes ir toliau vis daugiau sužinome apie aukštos miego kokybės svarbą, kad mūsų smegenys ir kūnas veiktų aukščiausiame lygyje.

Tačiau daugelis skirtingų veiksnių gali trukdyti geram nakties miegui ir sutrikdyti natūralų melatonino išsiskyrimo laiką organizme.

Tačiau neseniai atlikti tyrimai rodo, kad melatoninas veikia daug daugiau, nei tiesiog padeda miegoti.

 

Melatoninas: Įvadas

Melatoninas yra hormonas, kurį išskiria kankorėžinė liauka smegenyse.

Pati medžiaga padeda reguliuoti kitus hormonus ir išlaikyti natūralų cirkadinį ritmą organizme. Tai yra mūsų vidinis „laikrodis“, kuris vaidina svarbų vaidmenį, kai mes pabundame ir einame miegoti.

 

Cirkadiniu ritmu vadinami organizme vykstantys ir reguliariai maždaug kas 24 valandas pasikartojantys biologiniai procesai. Tai tokie procesai kaip hormonų išskyrimas, mityba, miegas ir panašiai.

 

Tai tiesiogiai veikia mūsų suvokimą dėl šviesos ir tamsos; tamsoje kūnas išsiskiria daugiau melatonino ir mes tampame mieguisti, kai šviesu – kūnas gamina mažiau melatonino, mes esame labiau budrūs ir judrūs.

Normalius melatonino gamybos ir išleidimo ciklus gali sutrikdyti išoriniai veiksniai. Pavyzdžiui, stresas, senėjimas, specifiniai vaistai, papildai ir netgi apšvietimas naktį gali sutrikdyti miego ciklą.

Daugelis mokslininkų teigia, kad ilgalaikis mūsų natūralaus melatonino gamybos ciklo sutrikimas gali sukelti neigiamą poveikį, galbūt net vėžį ir sutrumpintą gyvenimo trukmę.

 

Kaip Veikia Melatoninas

Šviesos būvimas kontroliuoja, kiek melatonino yra gaminama ir išleidžiama. Kai tamsu, smegenų liauka signalizuoja, kad pradeda gaminti ir išskirti melatoniną. Kai šviesa pasiekia regos nervą, kankorėžinė liauka yra signalizuojama, kad nedelsiant nutrauktų šio natūralaus miego hormono gamybą.melatoninas-hormonas

Deja, kai ciklas buvo nutrauktas, gali būti sunku jį vėl pradėti. Tai yra priežastis, kodėl, pabudus nakties viduryje ir įjungdami šviesą, gali būti sunku grįžti miegoti. Melatonino gamyba nėra iš karto grąžinama net ir tada, kai šviesa išnyksta. Štai todėl yra svarbu nenaudoji mobiliųjų prieš einant miegoti arba nubudus nakties metu.

Melatoninas taip pat įtakoja daugelį procesinių veiksnių mūsų kūne.

Tai apima moterų reprodukcinių hormonų paleidimo kontrolę. Tai gali padėti nustatyti, kada moteris pradeda menstruoti, dažnumas ir trukmė, ir kai ji pasiekia menopauzę.

Tyrėjai taip pat mano, kad melatonino kiekis mažėja, kai mes senstame, o vaikai turi aukščiausią melatonino lygį nakties metu. Mažesni melatonino lygiai iš tikrųjų gali būti susiję su miego sutrikimais ir gali paaiškinti, kodėl kartais mes linkę eiti miegoti vėliau ir pabusti anksčiau, kai mes senstame.

 

Neuroapsauginis Melatonino Poveikis

Taip pat yra daugybė būdų, kaip didelis melatonino lygis įtakoja bendrą smegenų sveikatą. Melatoninas iš tiesų yra labai galingas ir įvairiapusis antioksidantas. Jis saugo ir lipidus, ir baltymus nuo pažeidimų, taip pat yra susijęs laisvaisiais radikalais, kurių sudėtyje yra hidroksilo ir vandenilio peroksido (du labiausiai pavojingi ir kenkiantys laisvieji radikalai, esantys organizme).

Dalis, kaip melatoninas veikia smegenų ir neuronų apsaugoje, yra perėjimas per kraujo ir smegenų barjerą. Kadangi jis taip pat lengvai išsklaido į visas ląsteles ir patenka į centrinę nervų sistemą, tai leidžia lengvai „pritvirtinti“ smegenų neuronus.

 

Melatonino Miego Ciklai

Melatonino maisto papildai gali būt ypač naudingi žmonėms, turintiems nereguliarų darbo grafiką, arba, jei atrodo, kad negalima natūraliai miegoti.

Tai gali sumažinti laiką, per kurį reikia užmigti, taip pat padidinti bendrą miego trukmę ir miego kokybę.

Melatoninas gali padėti tiems, kurie užsiima pamaininiu darbu ar kenčia nuo įprastų miego ciklo pokyčių dėl kelionių.

Hormonas melatoninas gali paskatinti gilesnį REM miegą, galbūt net skatinti sąmoningą sapnavimą ir užtikrinti, kad nakties atminties konsolidavimo procesai būtų veiksmingesni.

 

Melatonino Vartojimas ir Dozavimas

Paprastai maisto papildo melatonino dozavimo intervalas yra 1 mg. per parą. Taip pat reikėtų pažymėti, kad beta blokatoriai, aspirinas ir kiti nesteroidiniai vaistai nuo uždegimo gali sumažinti bendrą melatonino gamybą organizme.

Vartojant alkoholį ar kitus sedatyvinius vaistus kartu su šiuo papildu, gali padidėti atsipalaidavimo ir sedacijos pojūtis (tai yra nerekomenduojama). Geriausias šio papildo vartojimo būdas yra naktį arba apie 30 minučių iki miego.

Šaltiniai
  1. Costello RB, Lentino CV, Boyd CC, O'Connell ML, Crawford CC, Sprengel ML, Deuster PA. The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature. Nutr J. 2014
  2. Tain YL, Huang LT, Chan JY. Transcriptional regulation of programmed hypertension by melatonin: an epigenetic perspective. Int J Mol Sci. 2014
  3. Hardeland R. Melatonin, noncoding RNAs, messenger RNA stability and epigenetics--evidence, hints, gaps and perspectives. Int J Mol Sci. 2014
  4. Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci. 2014
  5. Jenwitheesuk A, Nopparat C, Mukda S, Wongchitrat P, Govitrapong P. Melatonin regulates aging and neurodegeneration through energy metabolism, epigenetics, autophagy and circadian rhythm pathways. Int J Mol Sci. 2014
  6. Man GC, Wang WW, Yim AP, Wong JH, Ng TB, Lam TP, Lee SK, Ng BK, Wang CC, Qiu Y, Cheng CY. A review of pinealectomy-induced melatonin-deficient animal models for the study of etiopathogenesis of adolescent idiopathic scoliosis. Int J Mol Sci. 2014
  7. Laudon M, Frydman-Marom A. Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. Int J Mol Sci. 2014
  8. Reiter RJ, Tan DX, Galano A. Melatonin: exceeding expectations. Physiology (Bethesda). 2014
  9. Escribano BM, Colín-González AL, Santamaría A, Túnez I. The role of melatonin in multiple sclerosis, Huntington's disease and cerebral ischemia. CNS Neurol Disord Drug Targets. 2014
  10. Marseglia L, D'Angelo G, Manti S, Salpietro C, Arrigo T, Barberi I, Reiter RJ, Gitto E. Melatonin and atopy: role in atopic dermatitis and asthma. Int J Mol Sci. 2014
  11. Zhang HM, Zhang Y. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res. 2014
  12. Anderson G, Maes M. Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol Disord Drug Targets. 2014
  13. Reiter RJ, Tamura H, Tan DX, Xu XY. Melatonin and the circadian system: contributions to successful female reproduction. Fertil Steril. 2014
  14. Merrick L, Youssef D, Tanner M, Peiris AN. Does melatonin have therapeutic use in tinnitus? South Med J. 2014
  15. Tosini G, Owino S, Guillaume JL, Jockers R. Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease. Bioessays. 2014
  16. Mihandoost E, Shirazi A, Mahdavi SR, Aliasgharzadeh A. Can melatonin help us in radiation oncology treatments? Biomed Res Int. 2014
  17. Trivedi AK, Kumar V. Melatonin: an internal signal for daily and seasonal timing. Indian J Exp Biol. 2014
  18. Andersen LP, Werner MU, Rosenberg J, Gögenur I. A systematic review of peri-operative melatonin. Anaesthesia. 2014
  19. Vielma JR, Bonilla E, Chacín-Bonilla L, Mora M, Medina-Leendertz S, Bravo Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: a review. Acta Trop. 2014
  20. Vural EM, van Munster BC, de Rooij SE. Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of current literature. Drugs Aging. 2014
  21. Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014
  22. Luchetti F, Canonico B, Bartolini D, Arcangeletti M, Ciffolilli S, Murdolo G, Piroddi M, Papa S, Reiter RJ, Galli F. Melatonin regulates mesenchymal stem cell differentiation: a review. J Pineal Res. 2014
  23. Siah KT, Wong RK, Ho KY. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol. 2014
  24. Biran V, Phan Duy A, Decobert F, Bednarek N, Alberti C, Baud O. Is melatonin ready to be used in preterm infants as a neuroprotectant? Dev Med Child Neurol. 2014
  25. García JJ, López-Pingarrón L, Almeida-Souza P, Tres A, Escudero P, García-Gil FA, Tan DX, Reiter RJ, Ramírez JM, Bernal-Pérez M. Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review. J Pineal Res. 2014
  26. Acuña-Castroviejo D, Escames G, Venegas C, Díaz-Casado ME, Lima-Cabello E, López LC, Rosales-Corral S, Tan DX, Reiter RJ. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014
  27. Polimeni G, Esposito E, Bevelacqua V, Guarneri C, Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci (Landmark Ed). 2014
  28. Keijzer H, Smits MG, Duffy JF, Curfs LM. Why the dim light melatonin onset (DLMO) should be measured before treatment of patients with circadian rhythm sleep disorders. Sleep Med Rev. 2014
  29. Damiani JM, Sweet BV, Sohoni P. Melatonin: an option for managing sleep disorders in children with autism spectrum disorder. Am J Health Syst Pharm. 2014
  30. Gitto E, Marseglia L, Manti S, D'Angelo G, Barberi I, Salpietro C, Reiter RJ. Protective role of melatonin in neonatal diseases. Oxid Med Cell Longev. 2013
  31. Favero G, Rodella LF, Reiter RJ, Rezzani R. Melatonin and its atheroprotective effects: a review. Mol Cell Endocrinol. 2014
  32. Jaworek J, Leja-Szpak A. Melatonin influences pancreatic cancerogenesis. Histol Histopathol. 2014
  33. Lardone PJ, Alvarez-Sanchez SN, Guerrero JM, Carrillo-Vico A. Melatonin and glucose metabolism: clinical relevance. Curr Pharm Des. 2014
  34. Chojnacki C, Walecka-Kapica E, Romanowski M, Chojnacki J, Klupinska G. Protective role of melatonin in liver damage. Curr Pharm Des. 2014
  35. Jena G, Trivedi PP. A review of the use of melatonin in ulcerative colitis: experimental evidence and new approaches. Inflamm Bowel Dis. 2014
  36. Seko LM, Moroni RM, Leitao VM, Teixeira DM, Nastri CO, Martins WP. Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2014
  37. Scheuer C, Pommergaard HC, Rosenberg J, Gögenur I. Melatonin's protective effect against UV radiation: a systematic review of clinical and experimental studies. Photodermatol Photoimmunol Photomed. 2014
  38. Reiter RJ, Tan DX, Korkmaz A, Rosales-Corral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2014
  39. Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J. Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci. 2013
  40. Tamura H, Takasaki A, Taketani T, Tanabe M, Lee L, Tamura I, Maekawa R, Aasada H, Yamagata Y, Sugino N. Melatonin and female reproduction. J Obstet Gynaecol Res. 2014
  41. Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. J Pineal Res. 2013
  42. Keegan LJ, Reed-Berendt R, Neilly E, Morrall MC, Murdoch-Eaton D. Effectiveness of melatonin for sleep impairment post paediatric acquired brain injury: evidence from a systematic review. Dev Neurorehabil. 2014
  43. Silvestri M, Rossi GA. Melatonin: its possible role in the management of viral infections--a brief review. Ital J Pediatr. 2013
  44. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders. Curr Clin Pharmacol. 2014
  45. Rondanelli M, Faliva MA, Perna S, Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res. 2013
  46. Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets. 2013
  47. Sarlak G, Jenwitheesuk A, Chetsawang B, Govitrapong P. Effects of melatonin on nervous system aging: neurogenesis and neurodegeneration. J Pharmacol Sci. 2013
  48. Comai S, Gobbi G. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology. J Psychiatry Neurosci. 2014
  49. Boyce P, Hopwood M. Manipulating melatonin in managing mood. Acta Psychiatr Scand Suppl. 2013
  50. Hill SM, Cheng C, Yuan L, Mao L, Jockers R, Dauchy B, Blask DE. Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth. Curr Aging Sci. 2013
  51. Calvo JR, González-Yanes C, Maldonado MD. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res. 2013
  52. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer's disease. Int J Mol Sci. 2013
  53. Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R. Minireview: Toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. Mol Endocrinol. 2013
  54. Al-Omary FA. Melatonin: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2013
  55. de Rooij SE, van Munster BC. Melatonin deficiency hypothesis in delirium: a synthesis of current evidence. Rejuvenation Res. 2013
  56. Peschke E, Bähr I, Mühlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013
  57. Jain S, Besag FM. Does melatonin affect epileptic seizures? Drug Saf. 2013
  58. Rodriguez C, Martín V, Herrera F, García-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Sánchez-Sánchez AM, Suárez S, Puente-Moncada N, Anítua MJ, Antolín I. Mechanisms involved in the pro-apoptotic effect of melatonin in cancer cells. Int J Mol Sci. 2013
  59. Srinivasan V, Zakaria R, Jeet Singh H, Acuna-Castroviejo D. Melatonin and its agonists in pain modulation and its clinical application. Arch Ital Biol. 2012
  60. Shi L, Li N, Bo L, Xu Z. Melatonin and hypothalamic-pituitary-gonadal axis. Curr Med Chem. 2013
  61. Lanfumey L, Mongeau R, Hamon M. Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol Ther. 2013
  62. Espino J, Pariente JA, Rodríguez AB. Oxidative stress and immunosenescence: therapeutic effects of melatonin. Oxid Med Cell Longev. 2012
  63. Zeman M, Herichova I. Melatonin and clock genes expression in the cardiovascular system. Front Biosci (Schol Ed). 2013
  64. Lochner A, Huisamen B, Nduhirabandi F. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. Front Biosci (Elite Ed). 2013
  65. Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem. 2013
  66. Tamura H, Takasaki A, Taketani T, Tanabe M, Kizuka F, Lee L, Tamura I, Maekawa R, Asada H, Yamagata Y, Sugino N. Melatonin as a free radical scavenger in the ovarian follicle. Endocr J. 2013
  67. Lyseng-Williamson KA. Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years. Drugs Aging. 2012
  68. Suzen S. Melatonin and synthetic analogs as antioxidants. Curr Drug Deliv. 2013
  69. Huang H, Wang Z, Weng SJ, Sun XH, Yang XL. Neuromodulatory role of melatonin in retinal information processing. Prog Retin Eye Res. 2013
  70. Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res. 2012
  71. Srinivasan V, Ohta Y, Espino J, Pariente JA, Rodriguez AB, Mohamed M, Zakaria R. Metabolic syndrome, its pathophysiology and the role of melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2013
  72. Paulis L, Simko F, Laudon M. Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs. 2012
  73. Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012
  74. Cutando A, López-Valverde A, Arias-Santiago S, DE Vicente J, DE Diego RG. Role of melatonin in cancer treatment. Anticancer Res. 2012
  75. Pandi-Perumal SR, BaHammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, Hardeland R, Cardinali DP. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes. Neurotox Res. 2013
  76. Brigo F, Del Felice A. Melatonin as add-on treatment for epilepsy. Cochrane Database Syst Rev. 2012
  77. Russcher M, Koch B, Nagtegaal E, van der Putten K, ter Wee P, Gaillard C. The role of melatonin treatment in chronic kidney disease. Front Biosci (Landmark Ed). 2012
  78. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P. The role of melatonin in acute myocardial infarction. Front Biosci (Landmark Ed). 2012
  79. Hardeland R, Poeggeler B. Melatonin and synthetic melatonergic agonists: actions and metabolism in the central nervous system. Cent Nerv Syst Agents Med Chem. 2012
  80. Hardeland R. Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction. ScientificWorldJournal. 2012
  81. Sánchez-Hidalgo M, Guerrero JM, Villegas I, Packham G, de la Lastra CA. Melatonin, a natural programmed cell death inducer in cancer. Curr Med Chem. 2012
  82. Slats D, Claassen JA, Verbeek MM, Overeem S. Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res Rev. 2013
  83. Korkmaz A, Rosales-Corral S, Reiter RJ. Gene regulation by melatonin linked to epigenetic phenomena. Gene. 2012
  84. Olcese J, Lozier S, Paradise C. Melatonin and the circadian timing of human parturition. Reprod Sci. 2013
  85. Anderson G, Maes M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis. 2012
  86. Camacho ME, Carrion MD, Lopez-Cara LC, Entrena A, Gallo MA, Espinosa A, Escames G, Acuna-Castroviejo D. Melatonin synthetic analogs as nitric oxide synthase inhibitors. Mini Rev Med Chem. 2012
  87. Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this molecular handyman"?" Rev Med Virol. 2012
  88. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ. Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs. 2012
  89. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012
  90. Bellapart J, Boots R. Potential use of melatonin in sleep and delirium in the critically ill. Br J Anaesth. 2012
  91. Cardinali DP, Pagano ES, Scacchi Bernasconi PA, Reynoso R, Scacchi P. Melatonin and mitochondrial dysfunction in the central nervous system. Horm Behav. 2013
  92. Chen YC, Tain YL, Sheen JM, Huang LT. Melatonin utility in neonates and children. J Formos Med Assoc. 2012
  93. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Rueda N. Breast cancer therapy based on melatonin. Recent Pat Endocr Metab Immune Drug Discov. 2012
  94. Carpentieri A, Díaz de Barboza G, Areco V, Peralta López M, Tolosa de Talamoni N. New perspectives in melatonin uses. Pharmacol Res. 2012
  95. Nduhirabandi F, du Toit EF, Lochner A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf). 2012
  96. Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des. 2011
  97. Singhal NK, Srivastava G, Agrawal S, Jain SK, Singh MP. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol Neurobiol. 2012
  98. Reiter RJ, Coto-Montes A, Boga JA, Fuentes-Broto L, Rosales-Corral S, Tan DX. Melatonin: new applications in clinical and veterinary medicine, plant physiology and industry. Neuro Endocrinol Lett. 2011
  99. Cardinali DP, Pagano ES, Scacchi Bernasconi PA, Reynoso R, Scacchi P. Disrupted chronobiology of sleep and cytoprotection in obesity: possible therapeutic value of melatonin. Neuro Endocrinol Lett. 2011
  100. Rosales-Corral SA, Acuña-Castroviejo D, Coto-Montes A, Boga JA, Manchester LC, Fuentes-Broto L, Korkmaz A, Ma S, Tan DX, Reiter RJ. Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. J Pineal Res. 2012
  101. Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov. 2011
  102. Khan S, Heussler H, McGuire T, Dakin C, Pache D, Cooper D, Norris R, Flenady V, Charles B. Melatonin for non-respiratory sleep disorders in visually impaired children. Cochrane Database Syst Rev. 2011
  103. Chen CQ, Fichna J, Bashashati M, Li YY, Storr M. Distribution, function and physiological role of melatonin in the lower gut. World J Gastroenterol. 2011
  104. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012
  105. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011
  106. Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012
  107. Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol Paris. 2011
  108. Lanoix D, Lacasse AA, Reiter RJ, Vaillancourt C. Melatonin: the smart killer: the human trophoblast as a model. Mol Cell Endocrinol. 2012
  109. Escames G, Ozturk G, Baño-Otálora B, Pozo MJ, Madrid JA, Reiter RJ, Serrano E, Concepción M, Acuña-Castroviejo D. Exercise and melatonin in humans: reciprocal benefits. J Pineal Res. 2012
  110. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011
  111. Reiter RJ, Tan DX, Korkmaz A, Ma S. Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression. Ann Med. 2012
  112. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res. 2011
  113. Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, Mao L, Dauchy E, Sauer LA. Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res. 2011
  114. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet. 2011
  115. Aversa S, Pellegrino S, Barberi I, Reiter RJ, Gitto E. Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. J Matern Fetal Neonatal Med. 2012
  116. Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther. 2011
  117. Rossignol DA, Frye RE. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol. 2011
  118. Quera Salva MA, Hartley S, Barbot F, Alvarez JC, Lofaso F, Guilleminault C. Circadian rhythms, melatonin and depression. Curr Pharm Des. 2011
  119. de Faria Poloni J, Feltes BC, Bonatto D. Melatonin as a central molecule connecting neural development and calcium signaling. Funct Integr Genomics. 2011
  120. Bubenik GA, Konturek SJ. Melatonin and aging: prospects for human treatment. J Physiol Pharmacol. 2011
  121. Banach M, Gurdziel E, Jędrych M, Borowicz KK. Melatonin in experimental seizures and epilepsy. Pharmacol Rep. 2011
  122. Guénolé F, Godbout R, Nicolas A, Franco P, Claustrat B, Baleyte JM. Melatonin for disordered sleep in individuals with autism spectrum disorders: systematic review and discussion. Sleep Med Rev. 2011
  123. Doyen C, Mighiu D, Kaye K, Colineaux C, Beaumanoir C, Mouraeff Y, Rieu C, Paubel P, Contejean Y. Melatonin in children with autistic spectrum disorders: recent and practical data. Eur Child Adolesc Psychiatry. 2011
  124. Cutando A, Aneiros-Fernández J, Aneiros-Cachaza J, Arias-Santiago S. Melatonin and cancer: current knowledge and its application to oral cavity tumours. J Oral Pathol Med. 2011
  125. Acuña Castroviejo D, López LC, Escames G, López A, García JA, Reiter RJ. Melatonin-mitochondria interplay in health and disease. Curr Top Med Chem. 2011
  126. Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol. 2010
  127. van Geijlswijk IM, Korzilius HP, Smits MG. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010
  128. de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry. 2010
  129. Brodsky VY, Zvezdina ND. Melatonin as the most effective organizer of the rhythm of protein synthesis in hepatocytes in vitro and in vivo. Cell Biol Int. 2010
  130. Gitto E, Aversa S, Reiter RJ, Barberi I, Pellegrino S. Update on the use of melatonin in pediatrics. J Pineal Res. 2011
  131. De Berardis D, Di Iorio G, Acciavatti T, Conti C, Serroni N, Olivieri L, Cavuto M, Martinotti G, Janiri L, Moschetta FS, Conti P, Di Giannantonio M. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets. 2011
  132. Radogna F, Diederich M, Ghibelli L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol. 2010
  133. Hong Y, Palaksha KJ, Park K, Park S, Kim HD, Reiter RJ, Chang KT. Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury. J Pineal Res. 2010
  134. Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, Piroddi M, Canesi L, Papa S, Galli F. Melatonin signaling and cell protection function. FASEB J. 2010

 

  • Melatoninas padeda mažinti subjektyvų laiko juostų skirtumo pajautimą
  • Melatoninas padeda mažinti laiko, reikalingo norint užmigti, trukmę
sužinoti daugiau
raw-powders-melatonin-melatoninas-10mg-3mg-1mg

Palikite komentarą